Introduction
Graves’ disease (GD) is the most common cause of hyperthyroidism, affecting 1.5% of the population. It is more prevalent in women than in men (F/M 7:1)1. The most frequent extra-thyroidal manifestation is Graves’ disease-associated orbitopathy (GO) affecting more females than males with an annual incidence of 0.016% and 0.003% respectively. This manifestation might lead to ocular adverse events as a corneal breakdown or an optic neuropathy in 3 to 5% of such patients. The European guidelines of Graves’ disease-associated orbitopathy was commissioned by The European Thyroid Association to provide guidelines for the management of GO. They recommend a high-dose intravenous glucocorticoids (IV GC) be considered as a first-line treatment for moderate-to-severe and active GO2.
Skeletal hemangiomas are rare benign tumors of blood vessels which occur most commonly in the vertebral bodies followed by the skull. These tumors account for 0.7% of bone neoplasma3.
We hereby report a case of a severe GO treated by IV GC who developed a frontal bone hemangioma four months after the treatment.